Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy
- 22 October 2015
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 17 (12) , 1-8
Abstract
Visceral and hepatic adiposities have been associated with both cardiovascular and liver disease and are of concern in HIV-infected persons in the modern era of combination antiretroviral therapy (ART). The development of therapeutic targets to reduce visceral and hepatic adiposities in HIV-infected persons has been slow, because of early reports that attributed the excess adiposity to specific antiretroviral drugs. Visceral adiposity was initially thought to occur as part of a protease inhibitor-induced “HIV-associated lipodystrophy syndrome.” Subsequent studies show that visceral adiposity is likely a result of effective ART, recovery of health, and the normal aging process. Visceral adiposity is an established risk factor for hepatic adiposity. Identifying drug targets for non-alcoholic fatty liver disease is under active investigation. The present review summarizes the recent literature on the pathogenesis of visceral and hepatic adiposities in HIV-infected persons, current therapeutic strategies, and novel interventions in HIV-infected and uninfected persons.Keywords
This publication has 86 references indexed in Scilit:
- Systematic Review of Antiretroviral-Associated Lipodystrophy: Lipoatrophy, but Not Central Fat Gain, Is an Antiretroviral Adverse Drug ReactionPLOS ONE, 2013
- Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C VirusGastroenterology, 2011
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseNew England Journal of Medicine, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic SteatohepatitisHepatology, 2009
- Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role?Atherosclerosis, 2009
- SteatohepatitisHepatology, 2008
- Fat Distribution in Women With HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Obesity alters gut microbial ecologyProceedings of the National Academy of Sciences, 2005
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998